medRxiv · Apr 2026
Does Medication Order Matter? Incident Dementia Risk When Gabapentin Is Added to Prior Dihydropyridine Calcium Channel Blocker Therapy: An Active-Comparator Cohort Study in Hypertensive Adults
By Green JW, Kaplan J, Ljubic B et al.
Abstract Background Older adults frequently take both gabapentinoids and dihydropyridine calcium channel blockers (DHP-CCBs), often started years apart as new conditions emerge. A common pattern is the late addition of gabapentin to a regimen that has long included a DHP-CCB. Prior work links concurrent gabapentinoid–DHP-CCB exposure to elevated incident dementia risk, but whether the order in which the two medications are introduced matters has not been examined. We asked whether incident dementia risk differs by the order in which gabapentinoid and DHP-CCB therapy are introduced . Methods Using the Rutgers Clinical Research Data Warehouse (2018–2024) and active-comparator new-user designs with IPTW Cox models, we examined two prescribing scenarios in a hypertensive cohort: gabapentin or pregabalin added after prior DHP-CCB exposure (forward sequence; N=7,141), and a DHP-CCB or ACE inhibitor/ARB added after chronic gabapentinoid therapy (reverse sequence; N=685). Results When gabapentin was added to a regimen that already included a DHP-CCB, incident dementia risk was elevated relative to pregabalin ( IPTW HR 2.44, 95% CI 1.06–5.63, p=0.036 ). When the order was reversed — a DHP-CCB added to chronic gabapentinoid therapy — no elevated risk was observed ( IPTW HR 0.64, 95% CI 0.17– 2.39 ). Pre-specified sensitivity analyses supported the forward-sequence finding. Conclusions In hypertensive older adults, the same two medications were associated with very different dementia signals depending on which was started first: elevated risk when gabapentin was added to chronic DHP-CCB therapy, no elevated signal in the reverse direction. The two prescribing sequences may not be clinically equivalent. If replicated, this pattern would support targeted medication review at the time gabapentin is added to regimens that already include a DHP-CCB.